Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial
| Autor: | Melanie Davies, Neslihan Bascil Tutuncu, Hertzel Gerstein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Research design
Blood Glucose Male medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Population Insulin Glargine Type 2 diabetes Diabetes mellitus Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents education Glycemic Aged Original Research Advanced and Specialized Nursing Glycated Hemoglobin education.field_of_study Insulin glargine business.industry Online Letters: Comments and Responses Clinical Care/Education/Nutrition/Psychosocial Research nutritional and metabolic diseases Odds ratio Middle Aged medicine.disease Insulin Long-Acting Regimen Treatment Outcome Diabetes Mellitus Type 2 Female business medicine.drug |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents. RESEARCH DESIGN AND METHODS Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C RESULTS Median A1C in the whole population was 6.4% at baseline; at 5 years, it was 6.2% with glargine treatment and 6.5% with standard care. Of those with diabetes at baseline, 60% using glargine and 45% using standard care had A1C CONCLUSIONS Systematic intervention with basal insulin glargine or standard care early in the natural history of dysglycemia can maintain glycemic control near baseline levels for at least 5 years, whether diabetes is present at baseline or not. Keeping mean A1C |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|